Source: Health Products Regulatory Authority (ZA) Revision Year: 2019 Publisher: Sanofi-aventis south africa (pty) ltd, 2 Bond Street, Midrand, 1685, South Africa
DORMONOCT 2 mg Tablets.
| Pharmaceutical Form |
|---|
|
Tablet. Light yellow, biconvex round tablets. “B” and “026” are engraved and separated by a score line on one side. The other side is neutral. |
Each tablet contains: 2 mg loprazolam as loprazolam mesylate.
Contains sugar (lactose monohydrate): 83,9 mg per tablet.
| Active Ingredient | Description | |
|---|---|---|
| Loprazolam |
Benzodiazepines have a widespread action as a result of their enhancing the release of gamma-aminobutyric acid (GABA). They are effective as anti-convulsants, muscle relaxants, anti-anxiety agents, pre-medications and sedative hypnotics. Loprazolam is indicated for the short-term treatment of insomnia including difficulty in falling asleep and/or frequent nocturnal awakenings. |
| List of Excipients |
|---|
|
Colloidal anhydrous silica |
2 mg tablets packed in blister packs of 30’s and 100’s.
Sanofi-aventis south africa (pty) ltd, 2 Bond Street, Midrand, 1685, South Africa
Q/2.2/355
Date registered: 15.01.1984
| Drug | Countries | |
|---|---|---|
| DORMONOCT | Netherlands, South Africa |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
